Trial Profile
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary) ; Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- 22 Dec 2022 Protocol amended with respect to disease, drug & patient number.
- 14 Dec 2022 Planned number of patients changed from 59 to 89.
- 14 Dec 2022 Planned End Date changed from 31 Dec 2023 to 31 Jul 2025.